

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 81433

Title: Antioxidant and anti-inflammatory agents in chronic liver diseases: molecular mechanisms and therapy

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05744914

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Russia

Author's Country/Territory: United States

Manuscript submission date: 2022-11-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-09 15:34

Reviewer performed review: 2022-11-17 15:23

Review time: 7 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous
	Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No

SPECIFIC COMMENTS TO AUTHORS

1. NAFLD has recently begun being regarded as MAFLD, metabolic-associated fatty liver disease – please elaborate on this new definition and its difference from the conventional NAFLD; 2. Please expand all abbreviations in Figure 3 and Table 1; 3.

Please elaborate on what Mastiha is and how it is used; 4. Besides empagliflozin, other agents of the gliflozin class (i.e., licogliflozin, dapagliflozin) are advancing through the development pipeline for NAFLD – please explain briefly why special attention is given to empagliflozin and not the other molecules; 5. I would recommend adding short blocks of information on some other signaling pathways implicated in CLD development, i.e. sirtuin, LOXL2, galectin, FXR etc.

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 81433

Title: Antioxidant and anti-inflammatory agents in chronic liver diseases: molecular mechanisms and therapy

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04929562

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2022-11-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-09 03:28

Reviewer performed review: 2022-11-18 02:09

Review time: 8 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript summarized some natural products that can be potential applied in all the stages of CLD, such as β -sitosterol, curcumin, and gastrodin. And introduced the clinical trials about the efficacy and safety of the natural products. The manuscript is important for understanding the potential of some natural products on alleviating or treating CLD. However, some revisions are necessary as bellow. 1. The title is too sample and can not reflect the main subject of the manuscript. 2. The abstract should reflect the mechanisms that natural products alleviate CLD summarized by the authors, and the diagram of mechanism should be added in the manuscript in place, accordingly.

3. 'Natural products' should be one of the Key Words of the manuscript. 4. The significance of the review should be emphasized in the Summary section. 5. Constructive perspectives are necessary for future's research.